Myriad Genetics: Nicole Lambert
Myriad Genetics has promoted Nicole Lambert to chief operating officer. Previously, Lambert headed up Myriad's oncology, women's health, and international business divisions and genetic testing laboratory operations. In her new role, Lambert will still report to Myriad CEO Paul Diaz. She will now be in charge of spearheading the company's strategic growth plans, expanding the markets for Myriad's molecular diagnostic products, and implementing operational improvements that allow the firm to better engage with patients and doctors.
NeoGenomics: David Eberhard
NeoGenomics has appointed David Eberhard as chief medical officer of Inivata, NeoGenomics' liquid biopsy-focused subsidiary. Eberhard will be in charge of the clinical and strategic development of the subsidiary's liquid biopsy tests, including the RaDaR test for minimal residual disease. He most recently served as senior medical director of oncology at Illumina and was previously the senior director of oncology development at Genomic Health, focusing on bringing the firm's OncotypeSEQ liquid biopsy test to market.
Epigenomics: Jens Ravens
Epigenomics AG appointed Jens Ravens as chief financial officer, effective Feb. 1, 2022. Ravens will also become a member of the executive board of Epigenomics, overseeing the company's financial and administrative functions. Ravens began his career at Deutsche Bank. He previously held several positions, including VP of controlling and finance and compliance and risk officer at Hermes Group. He also served as CFO and managing director of Pleon Germany and as CFO of Pleon Europe, and as finance director and member of the board of Interseroh CDI.
For additional recent items on executive appointments and promotions in omics and molecular diagnostics, please see the People in the News page on our website.